Equity Profile

SUPN

Supernus Pharmaceuticals, Inc.

Health CarePharmaceuticals$2.6B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Supernus Pharmaceuticals, Inc. is a healthcare company focused on developing and commercializing innovative treatments for neurological and psychiatric disorders....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs and generating revenue.

N/A

Revenue Growth

Revenue growth is crucial for understanding the company's market demand and overall business health.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

SUPN Q2-2026 Earnings Preview

Context

Company Snapshot

Supernus Pharmaceuticals, Inc. is a healthcare company focused on developing and commercializing innovative treatments for neurological and psychiatric disorders. With a market cap of $3 billion, its performance is closely watched as it navigates the competitive pharmaceutical landscape.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-78.10%

Avg Stock Reaction

+1.56%

Last Quarter Recap

In Q1 2026, Supernus reported an EPS of -$0.04, missing estimates significantly. The stock reacted positively the next day, gaining 1.15%.

Management Promises & Guidance

Focus on improving product pipeline.
Commitment to managing operational costs.
Plans to enhance market presence in key therapeutic areas.

Expectations

Wall Street Expectations

Overall, expectations are mixed as Supernus has struggled with profitability in recent quarters. Investors are keen to see if the company can turn around its earnings trajectory.

Bull Case

If Supernus can show improved EPS and revenue growth, it could signal a recovery in its business model, leading to increased investor confidence.

Bear Case

Continued losses and missed revenue targets could raise concerns about the company's viability and future growth prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

The EPS figure will be critical in assessing whether the company is making progress toward profitability.

How has R&D spending changed compared to previous quarters?

Changes in R&D spending can indicate the company's commitment to innovation and future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for a turnaround in Supernus's earnings, given recent improvements in product pipeline and market strategies.

Supporting Evidence

Despite recent losses, the company has shown resilience with a positive stock reaction after disappointing earnings.

The options market indicates significant movement, suggesting that traders expect a surprise, either positive or negative.

Insider buying activity suggests confidence in the company's future prospects.

Key Risk

If EPS comes in better than -$0.04, it could challenge the current negative sentiment and shift market perceptions.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate centers around whether Supernus can achieve profitability and growth amidst ongoing operational challenges.

Bull Confirmed If

A positive EPS of $0.10 or better would confirm the bull case and suggest a turnaround.

Bear Confirmed If

An EPS loss greater than -$0.10 would confirm the bear case and raise concerns about the company's future.

Pre-Earnings Positioning

Options Market

Implied Move

±19.16%

Historical Avg

±1.6%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened uncertainty around the earnings report.

Options are pricing ±19.2% while SUPN has averaged ±1.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

35.3%

Calls (300)P/C Ratio: 0.67Puts (400)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Supernus beats expectations, history suggests a stock increase of around +1.10%, confirming a positive outlook.

In-Line / Cautious

If results are in line but management is cautious, the stock may react neutrally, reflecting uncertainty.

Miss

A miss could lead to a decline of about +1.83%, reinforcing negative sentiment around the company's financial health.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

2 buys·0 sells

Members

House only

Est. Notional

$2,002.00–$30,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
2

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the product pipeline and upcoming launches.
2Details on cost management strategies and their impact on profitability.
3Insights into market demand for existing products.
4Management's outlook on future revenue growth.
5Any commentary on competitive pressures in the pharmaceutical industry.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Supernus Pharmaceuticals, Inc. is a healthcare company focused on developing and commercializing innovative treatments for neurological and psychiatric disorders....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs and generating revenue.

N/A

Revenue Growth

Revenue growth is crucial for understanding the company's market demand and overall business health.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

SUPN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-78.10%

Avg Stock Reaction

+1.56%

Last Quarter Recap

In Q1 2026, Supernus reported an EPS of -$0.04, missing estimates significantly. The stock reacted positively the next day, gaining 1.15%.

Management Promises & Guidance

Focus on improving product pipeline.
Commitment to managing operational costs.
Plans to enhance market presence in key therapeutic areas.

Expectations

Wall Street Expectations

Overall, expectations are mixed as Supernus has struggled with profitability in recent quarters. Investors are keen to see if the company can turn around its earnings trajectory.

Bull Case

If Supernus can show improved EPS and revenue growth, it could signal a recovery in its business model, leading to increased investor confidence.

Bear Case

Continued losses and missed revenue targets could raise concerns about the company's viability and future growth prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

The EPS figure will be critical in assessing whether the company is making progress toward profitability.

How has R&D spending changed compared to previous quarters?

Changes in R&D spending can indicate the company's commitment to innovation and future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for a turnaround in Supernus's earnings, given recent improvements in product pipeline and market strategies.

Supporting Evidence

Despite recent losses, the company has shown resilience with a positive stock reaction after disappointing earnings.

The options market indicates significant movement, suggesting that traders expect a surprise, either positive or negative.

Insider buying activity suggests confidence in the company's future prospects.

Key Risk

If EPS comes in better than -$0.04, it could challenge the current negative sentiment and shift market perceptions.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate centers around whether Supernus can achieve profitability and growth amidst ongoing operational challenges.

Bull Confirmed If

A positive EPS of $0.10 or better would confirm the bull case and suggest a turnaround.

Bear Confirmed If

An EPS loss greater than -$0.10 would confirm the bear case and raise concerns about the company's future.

Pre-Earnings Positioning

Options Market

Implied Move

±19.16%

Historical Avg

±1.6%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened uncertainty around the earnings report.

Options are pricing ±19.2% while SUPN has averaged ±1.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

35.3%

Calls (300)P/C Ratio: 0.67Puts (400)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Supernus beats expectations, history suggests a stock increase of around +1.10%, confirming a positive outlook.

In-Line / Cautious

If results are in line but management is cautious, the stock may react neutrally, reflecting uncertainty.

Miss

A miss could lead to a decline of about +1.83%, reinforcing negative sentiment around the company's financial health.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

2 buys·0 sells

Members

House only

Est. Notional

$2,002.00–$30,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
2

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the product pipeline and upcoming launches.
2Details on cost management strategies and their impact on profitability.
3Insights into market demand for existing products.
4Management's outlook on future revenue growth.
5Any commentary on competitive pressures in the pharmaceutical industry.